135 related articles for article (PubMed ID: 30199382)
1. Etanercept for Ankylosing Spondylitis With Coexisting Demyelinating Myelitis.
Ye C; Geng Z; Li S; Yu F
Am J Ther; 2019; 26(5):e629-e631. PubMed ID: 30199382
[No Abstract] [Full Text] [Related]
2. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis.
Wendling D; Nueffer JP
Joint Bone Spine; 2018 Dec; 85(6):769. PubMed ID: 29787812
[No Abstract] [Full Text] [Related]
3. Maintenance of Low Disease Activity following Tumor Necrosis Factor Inhibitor Dose Tapering in Ankylosing Spondylitis.
Steel L; Gaffney K
J Rheumatol; 2017 Aug; 44(8):1292. PubMed ID: 28765347
[No Abstract] [Full Text] [Related]
4. Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.
Omair MA; Alnaqbi KA; Lee P
Clin Rheumatol; 2012 Aug; 31(8):1259-61. PubMed ID: 22644089
[TBL] [Abstract][Full Text] [Related]
5. Radiographic Evidence of Hip Joint Recovery in Patients with Ankylosing Spondylitis after Treatment with Anti-tumor Necrosis Factor Agents: A Case Series.
Song R; Chung SW; Lee SH
J Rheumatol; 2017 Nov; 44(11):1759-1760. PubMed ID: 29093078
[No Abstract] [Full Text] [Related]
6. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
7. Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.
van der Weijden MA; van Denderen JC; Lems WF; Nurmohamed MT; Dijkmans BA; van der Horst-Bruinsma IE
J Rheumatol; 2016 Apr; 43(4):758-64. PubMed ID: 26879348
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
9. Demyelination during anti-TNFα therapy for ankylosing spondylitis.
Mercieca C; Vella N; Borg AA
Mod Rheumatol; 2012 Apr; 22(2):303-7. PubMed ID: 21748364
[TBL] [Abstract][Full Text] [Related]
10. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
[TBL] [Abstract][Full Text] [Related]
11. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
Sieper J; Appel H; Braun J; Rudwaleit M
Arthritis Rheum; 2008 Mar; 58(3):649-56. PubMed ID: 18311819
[No Abstract] [Full Text] [Related]
12. A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
Zeremski V; Savić A; Ilić T; Milosević I; Maksimović M; Vucković B
Srp Arh Celok Lek; 2016; 144(1-2):81-4. PubMed ID: 27276864
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
[TBL] [Abstract][Full Text] [Related]
18. Etanercept in adult patients with early onset ankylosing spondylitis.
Inman RD; Clegg DO; Davis JC; Whitmore JB; Solinger A
J Rheumatol; 2006 Aug; 33(8):1634-6. PubMed ID: 16881118
[TBL] [Abstract][Full Text] [Related]
19. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
Dong Y; Li P; Xu T; Bi L
Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
[TBL] [Abstract][Full Text] [Related]
20. An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus.
Schulte-Wrede U; Sörensen T; Grün JR; Häupl T; Hirseland H; Steinbrich-Zöllner M; Wu P; Radbruch A; Poddubnyy D; Sieper J; Syrbe U; Grützkau A
Arthritis Res Ther; 2018 Aug; 20(1):191. PubMed ID: 30157966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
